Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BD Sensability Breast Self-Exam Aid Available In Pharmacies Nationwide

This article was originally published in The Gray Sheet

Executive Summary

The first breast self-examination aid to be cleared by FDA is now available in pharmacies nationwide through distributor BD (formerly Becton Dickinson). A direct-to-consumer television ad campaign is scheduled to begin in October, the firm reported Sept. 14.

You may also be interested in...

Inventive Products seeking to be acquired after Sensor Pad OTC clearance.

INVENTIVE PRODUCTS, INC. SEEKING ACQUISITION PARTNER TO MARKET SENSOR PAD breast exam aid in the wake of FDA's Nov. 14 clearance of the device for OTC use. The privately held, Decatur, Illinois-based firm says that it lacks the resources to effectively market and distribute the product nationally and company hopes to find a larger firm -- with which to merge. Sensor Pad consists of two layers of plastic filled with a silicon lubricant and is used as an aid for women in conducting breast self-examinations.

UK Grants First Worldwide Authorization For PfIzer/BioNTech COVID-19 Vaccine

The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.

Wockhardt Preps To Deliver 100M Doses Of AZ Vaccine

As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts